InvestorsHub Logo
Followers 36
Posts 1166
Boards Moderated 0
Alias Born 03/07/2013

Re: None

Thursday, 04/30/2020 12:10:18 PM

Thursday, April 30, 2020 12:10:18 PM

Post# of 97081
Another potential windfall for the company is the RADx competition announced yesterday by the NIH. RADx

Should DECN pass the Specialty Labs clinical testing in the US (Note: it is clear in their Mar 3 PR that all their products undergo clinical testing in South Korea prior to introduction to US.), then with their 2nd test strip for at home use, they should be an excellent candidate for and to possibly win the RADx competition which would radically change the whole projection of the company as the "go-to" two product COVID-19 testing company KB has stated is their goal.

If nothing else, I would expect DECN to enter their products, product designs in to the RADx competition and that alone is going to give them further exposure.

If their test strips for COVID-19 have already passed clinical testing in South Korea before being submitted to US Pre-EUA, you can understand the confidence and projections KB has had in his PRs.

I agree he might need to hire someone to review or produce those going forward, but thus far things have moved forward at a quick pace and according to what he has stated in his PRs regarding the development of the product and I expect as well as hope certainly to hear about some positive test results within the next couple of weeks. If it comes out before May 8th, it's a bonus.